Singapore, Feb. 12 -- Fujifilm Biotechnologies, a world leading contract development and manufacturing organisation (CDMO) for biologics, vaccines, and advanced therapies, recently announced the grand opening of its expanded site in Teesside, UK.

The significantly expanded presence, funded through a total investment of approximately £400 million from Fujifilm Corporation, Japan, includes the opening of the largest single-use biopharmaceutical CDMO facility in the UK, located at the existing Fujifilm Biotechnologies site.

The UK expansion represents the newest addition to Fujifilm Biotechnologies' global manufacturing network and introduces 2,000 L and 5,000 L single-use bioreactors with a total capacity up to 19,000 L to provide sm...